COVID-19
The US Food and Drug Administration (FDA) is adopting a more nuanced approach to COVID-19 vaccine approvals, requiring robust evidence for certain groups to warrant future approvals. According to FDA Commissioner Marty Makary, M.D., and Center for Biologics Evaluation and Research (CBER) head Vinay Prasad, M.D., the agency&
COVID-19
The Food and Drug Administration (FDA) has announced a significant shift in its approach to Covid-19 boosters, limiting access to healthy Americans under 65 without clear evidence of clinical benefit. In a commentary piece published in the New England Journal of Medicine, FDA Commissioner Marty Makary and Vinay Prasad, director
COVID-19
The Food and Drug Administration (FDA) is redefining its approach to COVID-19 vaccine approval, shifting its focus towards prioritizing high-risk groups, including older adults and those with certain health conditions. This change marks a significant shift in the agency's strategy, narrowing the scope of vaccine eligibility to those
COVID-19
Scientists have been studying messenger RNA (mRNA) for decades, discovering its potential in preventing infectious diseases and treating cancer and rare diseases. However, there has been controversy surrounding the safety of mRNA vaccines against Covid-19. Health Secretary Robert F. Kennedy Jr. has questioned their safety, and state legislatures are considering
COVID-19
Novavax's Nuvaxovid, the only recombinant protein-based non-mRNA COVID-19 vaccine available in the U.S., has received approval from the U.S. Food and Drug Administration (FDA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years
COVID-19
Researchers from Nanjing University have made a significant breakthrough in developing a high-lethality precision-guided nanomissile for broad-spectrum virucidal and anti-inflammatory therapy. This innovative treatment has the potential to eradicate viral infectivity and inflammatory storm suspension, offering a new hope in the fight against COVID-19. Key Takeaways: * The nanomissile is a
COVID-19
Researchers from the University of Washington conducted a study to understand the factors contributing to the low uptake of shingles vaccines among older adults. The study, published in PLOS ONE, analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) in Virginia from 2018, 2019, and 2021. The findings suggest
COVID-19
The U.S. Food and Drug Administration has granted full approval to Novavax's COVID-19 vaccine, but only for certain groups. The vaccine, the only protein-based COVID vaccine available in the U.S., is approved for adults ages 65 and older, or for people ages 12 to 64 who
COVID-19
The U.S. Food and Drug Administration has approved Novavax's COVID-19 vaccine, however, its use is restricted to older adults and those with underlying conditions that put them at risk. This decision comes after a delay in the approval process and raises concerns about the vaccine's
COVID-19
Molnupiravir and nirmatrelvir/ritonavir combination therapy has been found to be safe and well-tolerated in a Phase I de-escalation trial for treating mild to moderate COVID-19. The trial, AGILE CST-8 (NCT04746183), evaluated the combination therapy in adult out-patients with SARS-CoV-2 infection. The results showed that no participant starting with the
COVID-19
The US FDA has approved Novavax's protein-based COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older, as well as individuals between 12 and 64 with underlying health conditions. The vaccine has been available under emergency use authorization since July 2022. Novavax had initially sought approval for a broader
COVID-19
A retrospective study assessing the impact of the SARS-CoV-2 pandemic on dental healthcare workers (DHCWs) has been presented, revealing a concerning mortality rate among this group. The study, published in the International Dental Journal, highlights the increased risk of infection among DHCWs due to frequent exposure to aerosol-generating procedures. The
